*Include 3 bullets (< 30 words total) per slide – the most important messages associated with the particular slide*

Team name: ME Therapeutics Inc.

Date updated: September 1, 2019

|  |  |
| --- | --- |
| S1: Title  & Elevator Pitch/Headline | * IMPROVING IMMUNO-ONCOLOGY For COLORECTAL CANCER * IO has revolutionized cancer treatment but doesn’t work in colon cancer * Our new drug can make colon cancer responsive to IO |
| S2: The problem | * Current immunotherapy has proven effective against some late stage cancers * Many tumor types including CRC are resistant to current immunotherapies * Immunosuppressive cells make these tumors resistant to IO therapy |
| S3: The solution | * Current IO therapy works by stimulating T cells to attack cancer * Knocking down immunosuppressive cells can improve IO therapies * Synergy with new drugs is required to improve IO for cancer |
| S4: Product (how it addresses the problem) | * G-CSF expands MDSCs to create an immunosuppressive tumor environment * Our drug decreases the activity of MDSCs by neutralizing G-CSF * Removing MDSCs will enhance T cell function against cancer |
| S5: First Application | * Colon cancer has a high unmet need because IO is ineffective * G-CSF is highly expressed and promotes an immunosuppressive tumor environment * High G-CSF expression is associated with poor prognosis |
| S6:  Technology | * Our drug reduces MDSCs and increases T cells in colon cancer * Our drug decreases tumor counts and tumor size   Our drug is ready to test alone or in combination therapy |
| S7:  Competing approaches | * Current IO therapy is only effective for 5% of patients * Crowded pipeline with many combination therapies being tested * We have selected a unique approach targeting G-CSF |
| S8:  Team | * Founders have background in industry, academia and cancer immunology * We have 2 PhD scientists and rent space at UBC * Member of MIT IDEA2 Startup Incubator Program |
| S9:  Traction & summary | * We filed worldwide patents on 2 lead antibodies and own IP * Science validated by grant funding and support BC Cancer doctors * Blocking G-CSF will improve IO effectiveness against CRC |